Slide 1: TALi Digital Investor Presentation August 2021
For personal use only TALi DIGITAL (ASX: TD1) Investor Presentation August 2021 talidigital.com
Slide 2: Forward-looking statements
Forward-looking statements For personal use only Certain statements in this announcement are forward-looking statements. Forward-looking statements can generally be identified by the use of words such as “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “target”, “may”, “as
Slide 3: Overview: Delivering on the TALi growth strategy
Overview For personal use only Delivering on the TALi growth strategy. $ $ Licensing deal Milestone and International Beyond ADHD IP portfolio Exclusive US-market royalty payments markets Cognitive applications An IP portfolio that places licensing deal with global Significant expected Progressing a
Slide 4: Akili partnership
For personal use only Akili partnership Transformational deal with global market leader. TALi DIGITAL (ASX: TD1) Investor Presentation | August 2021 | 4
Slide 5: Akili Interactive
Akili Interactive For personal use only Akili is a global leader in digital therapeutics. ³ Private US-based company backed by leading venture capital firms EndeavourRx® ³ Flagship product is EndeavourRx® ³ Prescription digital treatment to improve attention function in children aged 8–12 years ³ Re
Slide 6: Significant milestones and royalty payments
Significant milestones and royalty payments For personal use only TALi will be entitled to receive estimated total milestone payments up to AU$51m (US$37.5m) plus royalties. Indicative timeframe Now FY23 FY23 onwards Additional clinical clearance FDA clearance Future sales/royalties ³ Clinical devel
Slide 7: Access to large and growing US market
Access to large and growing US market For personal use only Market opportunity1 ³ US is largest global market for treatment of ADHD globally 6m ³ Estimated spend per ADHD child is 5X neuro- children (8-18 years) typical child diagnosed with ADHD1 ³ 50% of ADHD patients willing to try non- US $10B ph
Slide 8: TALi's patented innovative platform
For personal use only TALi’s patented innovative platform Ushering in the next generation of digital therapeutics.
Slide 9: The brain and cognitive performance
The brain and cognitive performance For personal use only The concept of neuroplasticity and delivering evidence based digital solutions is at the core of who TALi is. ³ Neuroplasticity or brain plasticity is the ability of the brain to modify its connections or re-wire itself. Thus intervention (th
Slide 10: TALi vision
TALi vision For personal use only Personalised game changing experiences to enhance cognitive function and behaviour from any digital device.
Slide 11: TALi — proven digital assessment and training
TALi — proven digital assessment and training For personal use only A simple, low cost early detection and training platform: “TALi”. ³ Personalised digital interventions — complementary to current therapies ³ Software as a Medical Device (SAMD) delivered by prescription model DETECT TRAIN Digital a
Slide 12: Our journey
Our journey For personal use only Attention and related disorders — mass non-invasive screening/diagnosis and treatment is critical. Where did we start? Where are we headed? Target condition Target condition ³ Inattention and associated behavioural ³ Attention Deficit Hyperactivity Disorder conditio
Slide 13: Target condition: Inattention, ADHD, ASD
Target condition: Inattention, ADHD, ASD For personal use only The scale of the global paediatric cognitive opportunity. 136 million US$20B global 178% increase children drug therapy in prevalence Inattention ADHD (Attention Deficit ASD (Autism Spectrum Disorder) 136m children with severe attention
Slide 14: Target condition: MCI (Mild Cognitive Impairment)
Target condition: MCI (Mild Cognitive Impairment) For personal use only Other cognitive indications beyond ADHD. Over 6 million living with Deaths increased by 16% 1 in 3 seniors dies with Alzheimer’s Alzheimer’s during COVID or another dementia More than 6 million Americans are living In the United
Slide 15: Global leading IP portfolio
Global leading IP portfolio For personal use only Leveraging our patents to become a key ecosystem participant. Canada European Patent Exam requested Convention (and UK) (21 January 2020) Intention to grant declared (22 July 2021) Japan USA Patent granted Patent granted (23 October 2020) (14 April 2
Slide 16: Growth strategy
For personal use only Growth strategy Building partnerships and layering revenues.
Slide 17: TALi growth strategy
TALi growth strategy For personal use only The building blocks to revenue growth. $ $ Validate technology Expand application Layer recurring revenues Build international Clinical program in largest market: Beyond ADHD: Diversification: partnerships Working with global leaders: ³ Additional data and
Slide 18: Indian partnership strategy (The Times Group)
Indian partnership strategy (The Times Group) For personal use only Building diversified revenue base through direct to consumer model in India. Commercial rollout in India TALi entered an investment agreement and an advertising agreement with Brand India’s largest media conglomerate Capital Worldwi
Slide 19: Indian partnership strategy (The Times Group)
Indian partnership strategy (The Times Group) For personal use only Partnership provides priority US$1.5M pre-paid advertising credit remains available placements and marketing support for use (of total US$2M investment). to target consumers directly. BCI investment guarantees both priority advertis
Slide 20: Other business developments
Other business developments For personal use only TALi strategy to leverage US partnership providing foundation for other revenue opportunities. Progressing additional Additional clinical data commercial discussions in to support reimbursement other international markets submission in AU market ³ Po
Slide 21: TALi Digital Investment highlights
TALi Digital For personal use only Investment highlights. $ Market opportunity Evidence-first based A patented platform Clinically validated Market opportunities that dwarf An evidence-first based and A patented platform for cognitive FDA, TGA and CE-mark (TALi most others: US$20B global validated (
Slide 22: Appendices
For personal use only Appendices.
Slide 23: Board and management
Board and management For personal use only Sue MacLeman Jefferson Harcourt Dr David Brookes Glenn Smith Non-Executive Chair Non-Executive Director Non-Executive Director Managing Director Sue has more than 30 years’ Mr Harcourt has over 15 years Dr. Brookes has extensive Glenn Smith is an experience
Slide 24: Company and shareholder information
Company and shareholder information For personal use only Capital structure ASX code TD1 Share price (as at 13 August 2021) $0.046 per share Number of Shares on issue 931.9m Market capitalisation (as at 13 August 2021) $42.9m Options and warrants on issue - Cash balance (as at 30 June 2021) $2.7m Ma
Slide 25: Proven by science: TALi DETECT
Proven by science For personal use only Evidence shows TALi DETECT can be the new clinical standard. TALi DETECT Validity DETECT TEA-CH2 J Strength of Initial results highlight Using Structural equation modelling (SEM), it was confirmed that DETECT game game correlation Result program works in a sub
Slide 26: Proven by science: TALi TRAIN
Proven by science For personal use only Clinical evidence shows TALi TRAIN creates sustained benefits. TALi TRAIN Rationale Computerised This study aimed to assess the immediate and long-term efficacy of a attention training computerised attention training program (TALi TRAIN) on attentional Selecti
Slide 27: TALi — Personalised game changing experiences
For personal use only TALi — Personalised game changing experiences to enhance cognitive function and behaviour from any digital device. For further information please contact the TALi Digital team: e. info@talihealth.com | p. 1300 082 013 | w. talidigital.com